Resources from the same session
1621MO - Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update
Presenter: Robin Jones
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1622MO - Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
Presenter: John Zalcberg
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1623MO - Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Presenter: Filip Janku
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1624MO - Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)
Presenter: Javier Martin Broto
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1625MO - ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)
Presenter: Emanuela Palmerini
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1626MO - Treatment expectations and preferences for quality versus quantity of life in patients with advanced soft tissue sarcomas starting palliative 1st line chemotherapy
Presenter: Eugenie Younger
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1627MO - Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): A retrospective international series from the World Sarcoma Network
Presenter: Anna Maria Frezza
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1628MO - A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
Presenter: Georgios Kantidakis
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1629MO - First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
Presenter: Silvia Stacchiotti
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Jean-Yves Blay
Session: Mini Oral - Sarcoma
Resources:
Slides
Webcast